Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Hot Stocks Free for All ! » NNVC

 - UBBFriend: Email this page to someone!    
Author Topic: NNVC
greatimes
Member


Rate Member
Icon 1 posted      Profile for greatimes     Send New Private Message       Edit/Delete Post   Reply With Quote 
BusinessWire
12:52 p.m. 10/18/2006


A Company to Release Financials at the End of This Week
WEST HAVEN, Conn., Oct 18, 2006 (BUSINESS WIRE) -- NanoViricides (Pink Sheets: NNVC) President and Chairman, Dr. Anil Diwan, presented preliminary data on animal studies that compare nanoviricides drug candidates with oseltamivir (Tamiflu(R) Roche) on Friday, Oct. 13th at the 7th Annual Targeted Nano-delivery Conference in Baltimore, MD.

"Mice treated with the FluCide(TM)-I nanoviricide drug survived 186 hours (7.75 days, or 2.75 days more than control mice), whereas those treated with oseltamivir at twice the usual amounts normally used in such studies survived for only 151 hours (6.3 days, or only about 1.3 days longer than control). The experiment was designed with an aggressive infection level of common influenza such that control mice survived only 120 hours (5.0 days)," Dr. Diwan reported at the Conference. He also reported that all nanoviricides drug candidates tested were found to be superior to oseltamivir in this study. The studies were conducted by Dr. Krishna Menon under the auspices of KARD Scientific, Inc. in a blind study at a facility in Cambridge, MA. Dr. Mennon commented, "No obvious toxic effects were observable for the nanoviricide drugs. Therefore we believe the dosage of the nanoviricide drugs can be substantially increased to their therapeutic levels. This is expected to lead to a greatly enhanced therapeutic effect. This test was designed only to establish comparative baselines. Future experiments will be designed to assess the full therapeutic dosage levels and their efficacies."

NanoViricides, Inc. believes that at present no other anti-influenza drug candidate has shown results that are anywhere close to the results obtained with nanoviricides, both in terms of the in vitro data in H5N1 (presented earlier) and the in vivo data against common influenza.

In other news, NanoViricides announced it is on target to release its financials by the end of this week.

About NanoViricides - http://www.nanoviricides.com

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.

NanoViricides, Inc. Leo Ehrlich, 917-853-6440 leo*nanoviricides.com


Copyright Business Wire 2006

Posts: 60 | From: boston | Registered: Nov 2003  |  IP: Logged | Report this post to a Moderator
greatimes
Member


Rate Member
Icon 1 posted      Profile for greatimes     Send New Private Message       Edit/Delete Post   Reply With Quote 
here is the link to the financials

http://www.pinksheets.com/quote/finance.jsp?symbol=NNVC

Posts: 60 | From: boston | Registered: Nov 2003  |  IP: Logged | Report this post to a Moderator
greatimes
Member


Rate Member
Icon 1 posted      Profile for greatimes     Send New Private Message       Edit/Delete Post   Reply With Quote 
Yahoo!My Yahoo!Mail Make Y! your home pageYahoo! SearchSearch:Sign In
New User? Sign UpFinance Home -Help




Press Release Source: NanoViricides, Inc.


NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus
Monday May 7, 7:30 am ET


WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (Pink Sheets: NNVC - News) presented results of recent animal studies against rabies and BSL3 in vitro studies against a Clade 2 H5N1 (avian influenza) virus at the 23rd Annual Symposium of the Pan American Society for Clinical Virology in Tampa, FL, on Wednesday, May 2. (Pan American Society for Clinical Virology (PASCV): Clinical Virology Symposium)
ADVERTISEMENT


The BSL3 studies against Clade 2 H5N1, a Dec. 2006 isolate in Vietnam, showed that the nanoviricide developed against Highly Pathogenic Influenzas, FluCide-HP (TM), was highly effective in suppressing cytopathic effects (CPE), whereas the broad-spectrum nanoviricide against all influenzas, FluCide(TM), was slightly less effective than AviFluCide-HP. These findings were expected. Both of these candidates were significantly more effective than oseltamivir (Tamiflu®) in this blind study performed by the National Institute of Hygiene and Epidemiology (NIHE) scientists in Vietnam.

In addition, the antibody-fragment-based H5N1 specific (Clade 1, Vietnam, 2004-2005 strains) AviFluCide(TM) drug candidate was demonstrated conclusively by Vietnam scientists to significantly suppress CPE against this rgH5N1 strain (Clade 1), confirming previous results.

The Highly Pathogenic H5N1 subtype of influenza continues to rapidly evolve and is now found in two distinct subgroups, Clade 1 and Clade 2. According to CDC scientists, the Vietnam 2004/2005 strains belong to Clade 1, whereas the Indonesia 2006 (2007), Egypt 2006, and Vietnam 2006 (2007) strains are different and form the Clade 2 subgroup. The various Clade 2 strains are antigenically distinct from each other, but closer to each other than to Clade 1 strains.

"Highly Pathogenic Influenza strains of all clades possess the polybasic cleavage site. Thus FluCide-HP, designed against this site, is expected to be effective against all Highly Pathogenic influenza strains. It makes no difference to which type, subtype, or clade, they belong," said Anil R. Diwan, Ph.D., president of NanoViricides, Inc.

"We have shown that our drug candidates are the most effective drugs at present against even the newest subgroup of H5N1 viruses. Other companies continue to work on developing vaccines and drugs against the older Clade 1 H5N1 viruses, while we are working on the newest strains," said Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc.

The Company plans to comment shortly on its in vitro/in vivo rabies studies.

About NanoViricides: http://www.nanoviricides.com

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. Nanoviricides is currently developing drugs against Common influenza, Bird Flu H5N1, Rabies, Dengue and other viruses with various collaborators. The Company recently signed a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research (http://wrair-www.army.mil/) for creating new treatments for dengue fever using NanoViricides' virus-killing nanomedicine technology. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.


Contact:
NanoViricides, Inc.
Leo Ehrlich, 917-853-6440
leo*nanoviricides.com

--------------------------------------------------------------------------------
Source: NanoViricides, Inc.

Posts: 60 | From: boston | Registered: Nov 2003  |  IP: Logged | Report this post to a Moderator
T e x
Member


Icon 1 posted      Profile for T e x     Send New Private Message       Edit/Delete Post   Reply With Quote 
yikes...haven't seen this one in a while.

Interesting crew, as I recall...

--------------------
Nashoba Holba Chepulechi
Adventures in microcapitalism...

Posts: 21062 | From: Fort Worth | Registered: Apr 2005  |  IP: Logged | Report this post to a Moderator
greatimes
Member


Rate Member
Icon 1 posted      Profile for greatimes     Send New Private Message       Edit/Delete Post   Reply With Quote 
May 31, 2007 7:30 AM ETNew Images Show Virus Dismantled by Broad-Spectrum NanoViricides

NANOVIRICIDES INC (NNVC)

NanoViricides' President Dr. Anil Diwan unveiled the electron micrographs at the Nano Science and Technology Institute's (NSTI) Nanotech2007 Conference in Santa Clara, CA, May 24. An abstract of the presentation can be viewed at BioNano: NanoMedicine, Diagnostics, Imaging & Therapies.


The electron micrograph can be seen on the company's website at NanoViricides Dismantling MCMV as seen in TEM.

Different broad-spectrum nanoviricides were shown to dismantle the envelope coat of the murine cytomegalovirus, (mCMV) releasing the virus capsids it contains. The released capsids, which contain the genome of the virus particle, are no longer infectious. "This is the first visual demonstration that nanoviricides attack viruses in vitro just the way we've designed them to do so," said Dr. Diwan.

The murine CMV is closely related to the human CMV, which causes various diseases, including ocular diseases such as retinopathy and blindness, especially in immunocompromised patients such as HIV/AIDS cases. CMV has become a major management problem in persons living with AIDS and represents a therapeutic challenge to physicians caring for this population.

Dr. Diwan also presented survival data in mice infected with an otherwise lethal dose of rabies. "That the nanoviricides treatments enabled the animals to survive at all is a major breakthrough in rabies," he noted.

"We now know that our broad spectrum drug candidates are capable of attacking H5N1 bird flu viruses of both Clade 1 and Clade 2 varieties, common influenzas, rabies, and also cytomegalovirus," said NanoViricides' CEO Eugene Seymour, MD, MPH.

"Just as ampicillin works against a wide range of bacteria, we believe broad-spectrum nanoviricides can be designed to work against a wide range of viruses," he added further.

There can be no assurance that this demonstration or the results of our animal studies may ever lead to the development of a nanopharmaceutical product approved for commercial resale or that, if approved, a commercial market will develop for our products.

About NanoViricides: http://www.nanoviricides.com

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission. Contact Information: NanoViricides, Inc. Amanda Schuon, 310-550-7200 info*nanoviricides.com

Copyright 2007 BusinessWire

Posts: 60 | From: boston | Registered: Nov 2003  |  IP: Logged | Report this post to a Moderator
T e x
Member


Icon 1 posted      Profile for T e x     Send New Private Message       Edit/Delete Post   Reply With Quote 
NNVC moves to OTCBB:

http://www.otcbb.com/asp/dailylist_search.asp?DirectSymbol=NNVC&OTCBB=False

http://www.otcbb.com/asp/dailylist_detail.asp?mkt_ctg=OTCBB&d=06/27/2007

--------------------
Nashoba Holba Chepulechi
Adventures in microcapitalism...

Posts: 21062 | From: Fort Worth | Registered: Apr 2005  |  IP: Logged | Report this post to a Moderator
T e x
Member


Icon 1 posted      Profile for T e x     Send New Private Message       Edit/Delete Post   Reply With Quote 
can't remember if this was around 20-30 when we first followed the r/m when NNVC took over or whether it was .020-.030... but it went on to $3.75-ish before falling to currrent levels. This event has yet to be PR'd or even updated on pinksheets...

Supposedly, a $100k buy went through yesterday, a lil before noon... If somebody else could verify, would be helpful. tia

--------------------
Nashoba Holba Chepulechi
Adventures in microcapitalism...

Posts: 21062 | From: Fort Worth | Registered: Apr 2005  |  IP: Logged | Report this post to a Moderator
vg
Member


Member Rated:
4
Icon 1 posted      Profile for vg     Send New Private Message       Edit/Delete Post   Reply With Quote 
Yep, Tex you are right, I have been Holding this for over 2 years now, I bought at 9 cents and went to $3+ and now i'm just holding about 2000 free shares.
Posts: 510 | From: Dallas, TX | Registered: Apr 2005  |  IP: Logged | Report this post to a Moderator
T e x
Member


Icon 1 posted      Profile for T e x     Send New Private Message       Edit/Delete Post   Reply With Quote 
yes...how nice to see you, veeg!

You were in there as we looked this over...

What do you think of the dailylist post vs Pinksheets not being updated, etc...? These guys' PR "dept" always sucked, as I recall...

Love to hear to your take.

--------------------
Nashoba Holba Chepulechi
Adventures in microcapitalism...

Posts: 21062 | From: Fort Worth | Registered: Apr 2005  |  IP: Logged | Report this post to a Moderator
vg
Member


Member Rated:
4
Icon 1 posted      Profile for vg     Send New Private Message       Edit/Delete Post   Reply With Quote 
Tex, I'm not sure I got you question but I like the way the stock is moving
VG

Posts: 510 | From: Dallas, TX | Registered: Apr 2005  |  IP: Logged | Report this post to a Moderator
T e x
Member


Icon 1 posted      Profile for T e x     Send New Private Message       Edit/Delete Post   Reply With Quote 
The move to BB-land was not PR'd--found it on dailylist. Even "non-pump" companies usually PR stuff like that...make sense, yet?

Haven't looked, yet, but have seen posts indicating it's making a nice move...

where you been?

--------------------
Nashoba Holba Chepulechi
Adventures in microcapitalism...

Posts: 21062 | From: Fort Worth | Registered: Apr 2005  |  IP: Logged | Report this post to a Moderator
kywee
Member


Icon 1 posted      Profile for kywee     Send New Private Message       Edit/Delete Post   Reply With Quote 
Hm, this might be one to throw a little at and keep. I see a lot of quick 10% flips also. On my radar.
Posts: 2329 | From: MD | Registered: Jul 2005  |  IP: Logged | Report this post to a Moderator
greatimes
Member


Rate Member
Icon 1 posted      Profile for greatimes     Send New Private Message       Edit/Delete Post   Reply With Quote 
Press Release Source: Wall Street Reporter Magazine; NanoViricides, Inc., The Avicena Group, Inc., Bradmer Pharmaceuticals, Inc.


Wall Street Reporter Interviews Three Biopharmaceutical Company CEOs; Updates Investors On Groundbreaking Drug Delivery Methods, Acquisitions and Partnerships
Thursday November 15, 4:30 pm ET


NEW YORK, Nov. 15, 2007 (PRIME NEWSWIRE) -- Wall Street Reporter delivers exclusive interviews with Dr. Eugene Seymour, CEO of NanoViricides, Inc. (OTC BB:NNVC.OB - News); Dr. Belinda Tsao Nivaggioli, CEO of The Avicena Group, Inc. (OTC BB:AVGO.OB - News); and Alan Ezrin, CEO of Bradmer Pharmaceuticals, Inc. (Toronto:BMR.TO - News). The audio interviews are available at http://www.******************.com.
Dr. Eugene Seymour, CEO of NanoViricides, Inc. (OTC BB:NNVC.OB - News) tells Wall Street Reporter about the company's seven breakthrough anti-viral drugs. These drugs are the first to be designed to directly destroy viruses like HIV, Influenza, and E Bola. ``I know it sounds like science fiction, but it seems to be working,'' Dr. Seymour comments.

Highlights Include:


-- The unlimited market potential for the unique virus-attacking
drug lineup.

-- The drugs' revolutionary strategy of destroying viral cell
walls.

-- The company's strategic alliances with various government
agencies, including the Vietnamese Ministry of Health and the
Walter Reade Army Institute in the United States.

Posts: 60 | From: boston | Registered: Nov 2003  |  IP: Logged | Report this post to a Moderator
greatimes
Member


Rate Member
Icon 1 posted      Profile for greatimes     Send New Private Message       Edit/Delete Post   Reply With Quote 
NanoViricides Commences HIV Drug Animal TrialsApril 7, 2008 7:00 AM ET advertisement

Article tools E-mail this article Print-friendly version Discuss this articleStocks mentioned in this articleNanoViricides Inc (NNVC) Stock Quote, Chart, News, Add to WatchlistRelated newsNanoViricides to Begin HIV Animal TrialsDr. Howard Fields to Join NanoViricides as Vice-President of Virology
All BusinessWire newsNanoViricides, Inc. (OTC BB: NNVC.OB), said that preliminary animal trials of the Company's HIV therapeutic candidates have begun at a BioSafety Level 3 (BSL-3) Laboratory facility in Boston, MA. The initial results are expected before the end of next month. These animal studies will be conducted by Dr. Krishna Menon, PhD, VMD, MRCS, a world-renowned authority in preclinical and toxicological studies of innovative therapeutics.

"The purpose of this initial study is twofold: To assess therapeutic efficacy and to determine the appropriate dosages of drug that should be used in the later animal study," said Eugene Seymour, MD, MPH, CEO of NanoViricides, adding further, "if initial performance goals are met, it will be a critical first step in validating the Company's HivCide(TM)-I as a potential treatment for HIV/AIDS. An expanded follow-on study will then be performed by researchers at a prestigious federal research institute."

NanoViricides, Inc. is currently developing injectable formulations for systemic viral diseases such as HIV, human flu, bird flu (H5N1), Ebola, rabies and Dengue as well as eye drops for the virulent eye disease, epidemic keratoconjunctivitis (EKC). "We believe that in the future, many of the nanoviricides, including HivCide-I, can potentially be delivered using long-acting skin-patch formulations," said Dr. Seymour, adding, "if successful, such skin patches will be a very useful treatment strategy in combatting chronic diseases like HIV and Hepatitis C. Not having to remember to take pills or injections on a strict schedule will be extremely important in assuring patient compliance and treatment success".

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission. Contact Information: NanoViricides, Inc. Amanda Schuon, 310-550-7200 info*nanoviricides.com

Copyright 2008 BusinessWire

Posts: 60 | From: boston | Registered: Nov 2003  |  IP: Logged | Report this post to a Moderator
greatimes
Member


Rate Member
Icon 1 posted      Profile for greatimes     Send New Private Message       Edit/Delete Post   Reply With Quote 
NNVC News

http://biz.yahoo.com/bw/080505/20080505005617.html?.v=1

Posts: 60 | From: boston | Registered: Nov 2003  |  IP: Logged | Report this post to a Moderator
greatimes
Member


Rate Member
Icon 1 posted      Profile for greatimes     Send New Private Message       Edit/Delete Post   Reply With Quote 
Press Release Source: NanoViricides, Inc.


NanoViricides in Discussions with Pharma about EKC Eye Drug Candidate
Wednesday May 28, 7:00 am ET
Non-Disclosure Agreements Signed; Meetings Scheduled, says Company


WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that it has signed or has in attorney-review non-disclosure agreements with major pharmaceutical companies to enable further discussions regarding the Company’s nanoviricide drug candidate against Epidemic Kerato-Conjunctivitis (EKC). “We have already scheduled meetings to discuss the results of our recent animal studies against EKC,” said Eugene Seymour, MD, MPH, CEO of the Company, adding, “We have significant interest from several large pharma companies in both USA and abroad.”
ADVERTISEMENT


The Company has previously reported that it has received rapid and significant clinical response using a nanoviricide drug candidate eye-drop treatment in animal eyes. EKC was induced by Adenovirus 5 viral infection in this study. The study is now in its final stages and the biological samples collected will be analyzed over the next several weeks.

“We initiated the EKC project as a result of specific interest from certain pharmaceutical companies,” said Dr. Seymour. “We are very pleased with our initial success, despite the fact that adenovirus is a non-enveloped virus,” said Anil R. Diwan, PhD, President of the Company, adding, “It took us a very short time to develop and field a drug candidate against EKC; just a matter of months. This demonstrates the robustness of our underlying technology. We had strong theoretical basis in designing nanoviricide drug candidates against these non-enveloped adenoviruses.”

EKC is a severe and contagious viral infection of the eye in humans. It may cause impaired vision and may lead to blindness. EKC is primarily caused by adenoviruses, although some other viruses may also be the causative agent in humans. EKC may also be caused in some cases by bacterial infections, which are treatable with antibiotics. There is no treatment currently available for viral EKC.

The Company anticipates that the eye-drop formulation of the broad-spectrum nanoviricide drug candidate which was successful against adenoviral EKC may have significant potential against other viral EKC and the less severe viral conjunctivitis diseases as well. Viral conjunctivitis is highly contagious and occurs primarily in schools and other crowded settings, as well as in immuno-compromised populations. While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the treatment and prophylaxis market for EKC is expected to be of the order of several billion dollars annually.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.


Contact:
NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info*nanoviricides.com

--------------------------------------------------------------------------------
Source: NanoViricides, Inc.

Posts: 60 | From: boston | Registered: Nov 2003  |  IP: Logged | Report this post to a Moderator
a surfer
Member


Member Rated:
4
Icon 1 posted      Profile for a surfer     Send New Private Message       Edit/Delete Post   Reply With Quote 
http://stockcharts.com/charts/gallery.html?nnvc

Nice 2008 !!

Posts: 6410 | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
greatimes
Member


Rate Member
Icon 1 posted      Profile for greatimes     Send New Private Message       Edit/Delete Post   Reply With Quote 
Got some momo

http://stockcharts.com/charts/gallery.html?nnvc

Posts: 60 | From: boston | Registered: Nov 2003  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share